Table 1.

Patient Status at 5 Years

Status	No. of Patients (%)
	Dasatinib 100 mg Once Daily (n = 258)	Imatinib 400 mg Once Daily (n = 258)
On initial therapy at study end	158 (61)	162 (63)
Discontinued
Progression or treatment failure	28 (11)	36 (14)
Intolerance*	42 (16)	17 (7)
AE unrelated to study treatment	12 (5)	4 (2)
Poor compliance/nonadherence	1 (< 1)	7 (3)
Patient request	4 (2)	10 (4)
Withdrawal of consent	4 (2)	3 (1)
Lost to follow-up	1 (< 1)	2 (1)
Other	8 (3)†	16 (6)‡

Abbreviation: AE, adverse event.

^*As decided by investigator. Intolerance is defined as recurrent grade ≥ 3 hematologic toxicity or grade ≥ 2 nonhematologic toxicity requiring discontinuation despite dose reduction.

^†Includes insufficient molecular response (n = 3), pregnancy (n = 2), loss of complete cytogenetic response (n = 1), increased BCR-ABL1 (n = 1), and relocation to the United States (n = 1).

^‡Includes no molecular response/loss of molecular response (n = 4), suboptimal response (n = 3), insufficient cytogenetic response (n = 2), investigator request (n = 2), pregnancy (n = 1), recurrence of blasts in bone marrow (n = 1), no complete molecular response (n = 1), no major molecular response (n = 1), and appearance of mutation (n = 1).